Mies R
Med Klin. 1976 Nov 12;71(46):2013-6.
In a single blind study 25 out patients with exogenous obesity were treated for 6 weeks with Mazindol (2 mg one hour before lunch). The active treatment period was followed by a placebo period of 4 weeks. 9 out of 25 patients (group I) were asked to stick to a diet of 1000 cal daily for 14 days before entering the active treatment period. The rest of the patients (group II) were asked to start with this diet when entering the treatment period. There was practically no weight reduction during the initial 2 weeks on diet alone in group I. In both groups on Mazindol there was a significant weight reduction beginning after one week with a maximum weight loss of 4,1 and 5,1 kg respectively at the end of the active treatment period (2p less than 0,001). After the first week of the following placebo period there was an increase in weight in both groups (2p less than 0,01). During both treatment periods no changes in clinical (including) ergometric investigations) and laboratory findings were observed. However from these results no conclusions can be drawn regarding cardiopulmonary tolerance and abuse potential. In a few cases mild side effects related to the CNS have been found.
在一项单盲研究中,25名外源性肥胖门诊患者接受了为期6周的马吲哚治疗(午餐前1小时服用2毫克)。积极治疗期之后是为期4周的安慰剂期。25名患者中的9名(第一组)在进入积极治疗期之前被要求坚持每天1000卡路里的饮食14天。其余患者(第二组)在进入治疗期时被要求开始这种饮食。第一组仅靠饮食在最初2周内几乎没有体重减轻。在两组服用马吲哚的患者中,一周后开始显著减重,在积极治疗期结束时最大体重减轻分别为4.1千克和5.1千克(P<0.001)。在接下来安慰剂期的第一周后,两组体重均增加(P<0.01)。在两个治疗期内,未观察到临床(包括测力计检查)和实验室检查结果有变化。然而,从这些结果中无法得出关于心肺耐受性和滥用可能性的结论。在少数情况下,发现了与中枢神经系统相关的轻微副作用。